Screening of pancreatic lipase and α-glucosidase inhibitors from Chinese dietary herbs

Zhongguo Zhongyao Zazhi

Volumn 37, Issue 9, 2012, Pages 1319-1323

  Sun, Xiaoli ^a,b,c   Zhang, Kaibin ^b,c   Ji, Xiuhong ^c   Wang, Yanwen ^c   Zidichouski, Jeffrey ^c   Tong, Yan ^b   Gao, Huimin ^b   Zhang, Junzeng ^c   Wang, Zhimin ^a,b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^c NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

glucosidase inhibitor; Chinese dietary herbs; Lipase inhibitor; Screening

Indexed keywords

ACARBOSE; ALCOHOL; ALPHA GLUCOSIDASE; CURCUMA LONGA EXTRACT; MULBERRY EXTRACT; NELUMBO NUCIFERA EXTRACT; PIPER LONGUM EXTRACT; PLANT EXTRACT; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; WATER;

ARTICLE; CHINESE MEDICINE; CONTROLLED STUDY; DRUG POTENCY; DRUG SCREENING; ENZYME ACTIVITY; ENZYME ASSAY; IC 50; IN VITRO STUDY; NONHUMAN;

ALPHA-GLUCOSIDASES; CURCUMA; DRUGS, CHINESE HERBAL; ENZYME INHIBITORS; LIPASE; MORUS; NELUMBO; PANCREAS; PIPER; PLANT EXTRACTS;

EID: 84864439243     PISSN: 10015302     EISSN: None     Source Type: Journal    
DOI: 10.4268/cjcmm20120931     Document Type: Article

References (11)

1. Kopelman P G. Obesity as a medical problem[J]. Nature, 2000, 404: 635.
2. Mooradian A D. Obesity: a rational target for managing diabetes mellitus[J]. Growth Horm IGF Res, 2001, 11: S79.
3. Alemany M, Remesar X, Fernández-López J-A. Drug strategies for the treatment of obesity[J]. IDrugs, 2003, 6: 566.
4. JL Chiasson, R G Josse, R Gomis, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial[J]. Lancet, 2002, 359: 2072.
5. Sugiyama H, Shoji T, Yamaguchi, A, et al. Oligomeric procyanidins in apple polyphenol are main active components for inhibition of pancreatic lipase & triglyceride absorption[J]. J Agric Food Chem, 2007, 55(1), 4604.
6. Oki T, Matsui T, Osajima, Y. Inhibitory effect of a-glucosidase inhibitors varies according to its origin[J]. J Agric Food Chem, 1999, 47, 550.
7. Stumoll M, Haring H. Insulin resistance and insulin sensitizers[J]. Horm Res, 2001, 55(2): 3.
8. Ballinger A, Peikin S R. Orlistat: its current status as an anti-obesity drug[J]. Eur J Pharmacol, 2002, 440: 109.
9. Chao E C. A paradigm shift in diabetes therapy-dapagliflozin and other SGLT2 inhibitors[J]. Discov Med, 2011, 11(58): 255.
10. Strojek K, Yoon K, Hruba V, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomised, 24-week, doubleblind, placebo-controlled trial[J]. Diabetes Obes Metab, 2011, 13(10): 928.
11. Lucas C P, Boldrin M N, Reaven G M. Effect of orlistat added to diet (30% of calories from fat) on plasma lipids, glucose, and insulin in obese patients with hypercholesterolemia[J]. Am J Cardiol, 2003, 91: 961.